Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 14,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,571 Underlying: Common Stock · 14,000 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested as of the last day of the calendar quarter in which the Company first achieved cash flow break even after the grant date. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 14,000 | $19.43 | $272,020.00 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 14,000 | $1.12 | $15,694.00 |
DisclosureSEC source: 0001437749-19-018247 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,905 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-017142 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,905 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,905 | $18.07 | $178,983.35 |
DisclosureSEC source: 0001437749-19-017142 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.90 to $18.27, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,905 | $1.40 | $13,867.00 |
DisclosureSEC source: 0001437749-19-017142 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2019 Filed Aug 16, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-016957 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,904 Underlying: Common Stock · 9,000 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| August 13, 2019 Filed Aug 16, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $17.07 | $153,630.00 |
DisclosureSEC source: 0001437749-19-016957 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.13, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 13, 2019 Filed Aug 16, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $1.40 | $12,600.00 |
DisclosureSEC source: 0001437749-19-016957 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2019 Filed Aug 20, 2019 00:00 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-017139 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,905 Underlying: Common Stock · 9,000 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. F4 · balance_after: This Form 4/A is being filed solely to amend the total number of options remaining after the reported transaction due to a clerical error. All other information remains unchanged. Read SEC document |
| August 13, 2019 Filed Aug 20, 2019 00:00 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $17.07 | $153,630.00 |
DisclosureSEC source: 0001437749-19-017139 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.13, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 13, 2019 Filed Aug 20, 2019 00:00 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $1.40 | $12,600.00 |
DisclosureSEC source: 0001437749-19-017139 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,903 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,904 Underlying: Common Stock · 9,903 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,903 | $16.29 | $161,319.87 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,903 | $1.40 | $13,864.20 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,807 Underlying: Common Stock · 9,000 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| July 16, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $16.29 | $146,610.00 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.39, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 16, 2019 Filed Jul 19, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $1.40 | $12,600.00 |
DisclosureSEC source: 0001437749-19-014241 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,903 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,807 Underlying: Common Stock · 9,903 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,903 | $17.12 | $169,539.36 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.38, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,903 | $1.40 | $13,864.20 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 9,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,710 Underlying: Common Stock · 9,000 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $17.64 | $158,760.00 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.42 to $17.93, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $1.40 | $12,600.00 |
DisclosureSEC source: 0001437749-19-012005 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 7,088 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-010417 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,710 Underlying: Common Stock · 7,088 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,088 | $16.94 | $120,070.72 |
DisclosureSEC source: 0001437749-19-010417 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.91 to $17.39, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,088 | $1.40 | $9,923.20 |
DisclosureSEC source: 0001437749-19-010417 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2019 Filed Apr 13, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 7,088 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-007127 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,798 Underlying: Common Stock · 7,088 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| April 10, 2019 Filed Apr 13, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,088 | $17.91 | $126,946.08 |
DisclosureSEC source: 0001437749-19-007127 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 10, 2019 Filed Apr 13, 2019 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,088 | $1.40 | $9,923.20 |
DisclosureSEC source: 0001437749-19-007127 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 7,088 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-005090 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,886 Underlying: Common Stock · 7,088 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,088 | $17.19 | $121,842.72 |
DisclosureSEC source: 0001437749-19-005090 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,088 | $1.40 | $9,923.20 |
DisclosureSEC source: 0001437749-19-005090 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 02:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 35,497 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-003524 · rdgdoc.xml · derivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,497 Underlying: Common Stock · 35,497 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 02:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 35,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-003524 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,014 F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 7,088 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001437749-19-002787 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,974 Underlying: Common Stock · 7,088 shares Expires 2020-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,088 | $16.03 | $113,620.64 |
DisclosureSEC source: 0001437749-19-002787 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 02:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,088 | $1.40 | $9,923.20 |
DisclosureSEC source: 0001437749-19-002787 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 14,781 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-19-001005 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,781 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested as to 13,661 shares on February 27, 2010, and vested as to one thirty-sixth of the remaining balance of 40,981 shares on the 27th day of each of the ensuing 36 months. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 14,781 | $12.14 | $179,441.34 |
DisclosureSEC source: 0001437749-19-001005 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.09 to $12.19, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 14,781 | $1.26 | $18,624.06 |
DisclosureSEC source: 0001437749-19-001005 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 14,781 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-18-022029 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,781 Underlying: Common Stock · 14,781 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested as to 13,661 shares on February 27, 2010, and vested as to one thirty-sixth of the remaining balance of 40,981 shares on the 27th day of each of the ensuing 36 months. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 14,781 | $11.44 | $169,094.64 |
DisclosureSEC source: 0001437749-18-022029 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 14,781 | $1.26 | $18,624.06 |
DisclosureSEC source: 0001437749-18-022029 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-18-017771 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,562 Underlying: Common Stock · 12,540 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested as to 13,661 shares on February 27, 2010, and vested as to one thirty-sixth of the remaining balance of 40,981 shares on the 27th day of each of the ensuing 36 months Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $17.57 | $220,327.80 |
DisclosureSEC source: 0001437749-18-017771 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.35 to $17.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.26 | $15,800.40 |
DisclosureSEC source: 0001437749-18-017771 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-18-016715 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,102 Underlying: Common Stock · 12,540 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested as to 13,661 shares on February 27, 2010, and vested as to one thirty-sixth of the remaining balance of 40,981 shares on the 27th day of each of the ensuing 36 months. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,800 | $20.28 | $77,064.00 |
DisclosureSEC source: 0001437749-18-016715 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.28 to $20.30, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,200 | $21.55 | $90,510.00 |
DisclosureSEC source: 0001437749-18-016715 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,317 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.